<\/p>\n\n\n\n
Involving patients in healthcare research is well documented but can it work in lab-based research?<\/a> Connor, A. E., C. Hughes, L. Sch\u00e4fer, L. McNally, D. O. Raw, K. Bahramian, B. Carr, I. H. Dunne, J. Lysaght, S. A. O. Toole, J. C. Simpson and A. S. Perry<\/strong> ________________________________________________________________________________________________________________<\/p>\n\n\n\n Cannabidiol Inhibits the Proliferation and Invasiveness of Prostate Cancer Cells<\/a><\/p>\n\n\n\n O\u2019Reilly E, Khalifa K, Cosgrave J, Azam H, Prencipe M, Simpson JC, Gallagher WM, Perry AS<\/strong>.<\/p>\n\n\n\n Journal of Natural Products. 2023;86(9):2151-2161. doi:10.1021\/acs.jnatprod.3c00363. PMID: 37703852<\/p>\n\n\n\n ________________________________________________________________________________________________________________<\/p>\n\n\n\n ________________________________________________________________________________________________________________<\/p>\n\n\n\n SRF inhibitors reduce prostate cancer cell proliferation through cell cycle arrest in an isogenic model of castrate-resistant prostate cancer<\/a><\/p>\n\n\n\n Azam H, Maher S, Clarke S, Gallagher WM<\/strong>, Prencipe M<\/strong>.<\/p>\n\n\n\n Cell Cycle. 2023 Jul-Aug; 22(14-16):1759-1776. doi: 10.1080\/15384101.2023.2229713. Epub 2023 Jun 28. PMID: 37377210; PMCID: PMC10446773.<\/p>\n\n\n\n ________________________________________________________________________________________________________________<\/p>\n\n\n\n ________________________________________________________________________________________________________________<\/p>\n\n\n Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer<\/a><\/p>\n Silva R., Glennon K., Metoudi M., Moran B., Salta S., Slattedy K., Treacy A., Martin T., Shaw J., Doran P., Lynch L., Jeronimo C., Perry A.S.<\/strong>, Brennan D.J.<\/p>\n Int J Cancer.<\/em> 2023.1- 13. doi:10.1002\/ijc.34496. PMID:<\/span>36883413<\/span><\/p>\n ________________________________________________________________________________________________________________<\/p>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<\/p>\n Association of COVID-19 mortality with serum selenium, zinc and copper: Six observational studies across Europe<\/a><\/p>\n \n\n\n\n<\/p>\n Demircan K, Chillon TS, Bracken T, Bulgarelli I, Campi I, Laing GD, Fafi-Kremer S, Fugazzola L, Garcia AA, Heller R, Hughes DJ<\/strong>, Ide L, Klingenberg GJ, Komarnicki P, Krasinski Z, Lescure A, Mallon P, Moghaddam A, Persani L, Petrovic M, Ruchala M, Solis M, Vandekerckhove L, & Schomburg L.<\/p>\n \n\n\n\n<\/p>\n Front Immunol <\/em>2022, Nov 28;13:1022673. doi: 10.3389\/fimmu.2022.1022673. PMID: 36518764.<\/p>\n _______________________________________________________________________________________________________________________<\/p>\n Genetically Predicted Circulating Concentrations of Micronutrients and COVID-19 Susceptibility and Severity: A Mendelian Randomization Study<\/a><\/p>\n Daniel N, Bouras E, Tsilidis KK, Hughes DJ<\/strong>.\u00a0<\/p>\n Front Nutr<\/em> 2022, 9:842315. doi: 10.3389\/fnut.2022.842315. PMID: 35558754.<\/p>\n _______________________________________________________________________________________________________________________<\/p>\n The Associations of Selenoprotein Genetic Variants with the Risks of Colorectal Adenoma and Colorectal Cancer: Case\u2013Control Studies in Irish and Czech Populations<\/a><\/p>\n Mukhtar M, Ashfield N, Vodickova L, Vymetalkova V, Levy M, Liska V, Bruha J, Bendova P, O\u2019Sullivan J, Doherty G, Sheahan K, Nolan B, Vodicka P, & Hughes DJ<\/strong>.<\/p>\n Nutrient<\/em>s 2022, Jun 29;14(13):2718. doi: 10.3390\/nu14132718. PMID: 35807897<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n \n\n\n Plant-derived cannabinoids as anticancer agents<\/a><\/p>\n O’Reilly E.M., Cosgrave J.M., Gallagher W.M., Perry A.S.<\/strong><\/p>\n Trends Cancer<\/i>. 2022;8(5):350-357. doi:10.1016\/j.trecan.2022.01.017<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer<\/a><\/p>\n Azam H, Pierro L, Reina M, Gallagher WM<\/strong>, Prencipe M<\/strong>.<\/p>\n Expert Opin Ther Targets. 2022 Feb;26(2):155-169. doi: 10.1080\/14728222.2022.2032652. Epub 2022 Feb 11. PMID: 35114091.<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report<\/a><\/p>\n Silva R.,\u00a0<\/u>Moran B., Das S., Mulligan N., Doughty M., Treacy A., Sheahan K., Kelly C.M., Duffy A.G., Perry A.S.<\/strong>, Brennan D.J.<\/p>\n Case Reports in Women\u2019s Health. 2022. 34:e00395. doi:10.1016\/j.crwh.2022.e00395. PMID: <\/span>35198414<\/span><\/p>\n ________________________________________________________________________________________________________________<\/p>\n Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer<\/a><\/p>\n Silva R.,<\/u> Moran B., Baird AM, O\u2019Rourke C.J., Finn S.P., McDermott R., Watson W., Gallagher W.M., Brennan D.J., Perry A.S.<\/strong><\/p>\n Clin Epigenetics. 2022. 13(1):168. doi:10.1186\/s13148-021-01155-w. <\/span>PMID:34454584<\/span><\/p>\n _______________________________________________________________________________________________________________________<\/p>\n Epigenetics and precision medicine in prostate cancer<\/a><\/p>\n Jordan A.C., Prencipe M.<\/strong>,\u00a0Silva R.,\u00a0<\/u>Gallagher W.M., Perry A.S<\/strong>.<\/p>\n Epigenetics and Precision Medicine in Prostate Cancer.<\/em> Garcia-Gimenez J. (Ed.). Academic Press, 2022. 30:69-108. doi: 10.1016\/B978-0-12-823008-4.00008-1.<\/p>\n _______________________________________________________________________________________________________________<\/p>\n Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer<\/a><\/p>\n Watson RW, Azam H, Aura C, Russell N, McCormack J, Corey E, Morrissey C, Crown J, Gallagher WM<\/strong>, Prencipe M<\/strong>.<\/p>\n Cancers (Basel). 2020 Nov 27;12(12):3540. doi: 10.3390\/cancers12123540. PMID: 33260953; PMCID: PMC7760758.<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Evaluating liquid biopsies for methylomic profiling of prostate cancer.<\/a><\/p>\n Silva R, Moran B, Russell NM, Fahey C, Vlajnic T, Manecksha RP, Finn SP, Brennan DJ, Gallagher WM,\u00a0Perry AS<\/strong>.<\/p>\n Epigenetics. 2020 Jun-Jul;15(6-7):715-727. doi: 10.1080\/15592294.2020.1712876. Epub 2020 Jan 31.PMID:\u00a032000564<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.<\/a><\/p>\n Mazo C, Barron S, Mooney C,\u00a0Gallagher WM<\/strong>.Cancers (Basel). 2020 May 1;12(5):E1133. doi: 10.3390\/cancers12051133.PMID:\u00a032369904\u00a0Free article.<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer<\/a><\/p>\n Connell SP, O’Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS,\u00a0Perry AS<\/strong>, Clark J, Brewer DS.Prostate. 2020 May;80(7):547-558. doi: 10.1002\/pros.23968. Epub 2020 Mar 9.PMID:\u00a032153047<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells.<\/a><\/p>\n Bajor M, Graczyk-Jarzynka A, Marhelava K, Kurkowiak M, Rahman A, Aura C, Russell N, Zych AO, Firczuk M, Winiarska M,\u00a0Gallagher WM<\/strong>, Zagozdzon R.\u00a0\u00a0 Antioxidants (Basel). 2020 Apr 16;9(4):320. doi: 10.3390\/antiox9040320.PMID:\u00a032316111\u00a0Free PMC article.<\/strong><\/p>\n ________________________________________________________________________________________________________________<\/p>\n Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma.<\/a><\/p>\n Gutt\u00e0 C, Rahman A, Aura C, Dynoodt P, Charles EM, Hirschenhahn E, Joseph J, Wouters J, de Chaumont C, Rafferty M, Warren M, van den Oord JJ,\u00a0Gallagher WM<\/strong>, Rehm M.Cell Death Dis. 2020 Feb 13;11(2):124. doi: 10.1038\/s41419-020-2309-3.PMID:\u00a032054850\u00a0Free PMC article.<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Clinical Decision Support Systems in Breast Cancer: A Systematic Review.<\/a><\/p>\n Mazo C, Kearns C, Mooney C,\u00a0Gallagher WM<\/strong>.Cancers (Basel). 2020 Feb 6;12(2):369. doi: 10.3390\/cancers12020369.PMID:\u00a032041094\u00a0Free PMC article.\u00a0Review.<\/p>\n ________________________________________________________________________________________________________________<\/p>\n An EPR Strategy for Bio-responsive Fluorescence Guided Surgery with Simulation of the Benefit for Imaging.<\/a><\/p>\n Daly HC, Conroy E, Todor M, Wu D,\u00a0Gallagher WM<\/strong>, O’Shea DF.Theranostics. 2020 Feb 10;10(7):3064-3082. doi: 10.7150\/thno.42702. eCollection 2020.PMID:\u00a032194855\u00a0Free PMC article.<\/p>\n ________________________________________________________________________________________________________________<\/p>\n Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive\/HER2-Negative Patients: A TransATAC study.<\/a><\/p>\n Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O’Leary D,\u00a0Gallagher WM<\/strong>, Dowsett M, Cuzick J.Clin Cancer Res. 2020 Feb 1;26(3):623-631. doi: 10.1158\/1078-0432.CCR-19-0712. Epub 2019 Oct 22.PMID:\u00a031641007\u00a0.<\/p>\n _______________________________________________________________________________________________________________________<\/p>\n Holding a\u00a0MIR<\/em>ror up to the robustness of the prostate cancer urinary transcriptome<\/a><\/p>\n Connor AE, Jordan AC,\u00a0Perry AS<\/strong>.Transl Androl Urol. 2019 Dec;8(Suppl 5):S488-S490. doi: 10.21037\/tau.2019.09.25.PMID:\u00a032042627\u00a0Free PMC article.<\/p>\n _______________________________________________________________________________________________________________________<\/p>\n BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.<\/a><\/p>\n Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Vare\u0161lija D, Chin SF, Linn S, Young LS, Jirstr\u00f6m K, Crown JP, Bernards R, Caldas C,\u00a0Gallagher WM<\/strong>, O’Connor DP, N\u00ed Chonghaile T.<\/p>\n Clin Cancer Res. 2019 Dec 1;25(23):7139-7150. doi: 10.1158\/1078-0432.CCR-19-0713. Epub 2019 Aug 13.<\/p>\n PMID: 31409615<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive\/HER2-Negative Patients: A TransATAC study.<\/a><\/p>\n Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O’Leary D,\u00a0Gallagher WM<\/strong>, Dowsett M, Cuzick J.<\/p>\n Clin Cancer Res. 2019 Oct 22. doi: 10.1158\/1078-0432.CCR-19-0712. [Epub ahead of print]<\/p>\n PMID: 31641007<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference.<\/a><\/p>\n Charmsaz S, Collins DM,\u00a0Perry AS<\/strong>, Prencipe M.<\/strong><\/p>\n Cancers (Basel). 2019 Aug 7;11(8). pii: E1125. doi: 10.3390\/cancers11081125.<\/p>\n PMID: 31394729 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n RGD conjugated cell uptake off to on responsive NIR-AZA fluorophores: applications toward intraoperative fluorescence guided surgery.<\/a><\/p>\n Wu D, Daly HC, Grossi M, Conroy E, Li B,\u00a0Gallagher WM<\/strong>, Elmes R, O’Shea DF.<\/p>\n Chem Sci. 2019 Jun 21;10(29):6944-6956. doi: 10.1039\/c9sc02197c. eCollection 2019 Aug 7.<\/p>\n PMID: 31588261 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.<\/a><\/p>\n Miller IS, Shiels LP, Conroy E, Connor K, Dicker P,\u00a0Gallagher WM<\/strong>, Donovan NO, Kerbel RS, Crown J, Byrne AT.<\/p>\n Sci Rep. 2019 Jun 24;9(1):9204. doi: 10.1038\/s41598-019-45444-0.<\/p>\n PMID: 31235775 \u00a0<\/strong>Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.<\/a><\/p>\n Butler CT, Kennedy SA, Buckley A, Doyle R, Conroy E,\u00a0Gallagher WM<\/strong>, O’Sullivan J, Kennedy BN.<\/p>\n Oncotarget. 2019 Jun 4;10(38):3725-3744. doi: 10.18632\/oncotarget.26966. eCollection 2019 Jun 4.<\/p>\n PMID: 31217905 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.<\/a><\/p>\n Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D,\u00a0Perry AS<\/strong>, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I; Movember GAP1 Urine Biomarker Consortium, Parker C, Brewer DS, Cooper CS, Clark J.<\/p>\n BJU Int. 2019 May 20. doi: 10.1111\/bju.14811. [Epub ahead of print]<\/p>\n PMID: 31106513 \u00a0Free PMC Article<\/a><\/p>\n __________________________________________________________________________________________________________<\/p>\n A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.<\/a><\/p>\n Salvucci M, Rahman A, Resler AJ, Udupi GM, McNamara DA, Kay EW, Laurent-Puig P, Longley DB, Johnston PG, Lawler M, Wilson R, Salto-Tellez M, Van Schaeybroeck S, Rafferty M,\u00a0Gallagher WM<\/strong>, Rehm M, Prehn JHM.<\/p>\n JCO Clin Cancer Inform. 2019 Apr;3:1-17. doi: 10.1200\/CCI.18.00056.<\/p>\n PMID: 30995124 \u00a0Free Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n PDLIM2 Is a Marker of Adhesion and \u03b2-Catenin Activity in Triple-Negative Breast Cancer.<\/a><\/p>\n Cox OT, Edmunds SJ, Simon-Keller K, Li B, Moran B, Buckley NE, Bustamante-Garrido M, Healy N, O’Flanagan CH,\u00a0Gallagher WM<\/strong>, Kennedy RD, Bernards R, Caldas C, Chin SF, Marx A, O’Connor R.<\/p>\n Cancer Res. 2019 May 15;79(10):2619-2633. doi: 10.1158\/0008-5472.CAN-18-2787. Epub 2019 Mar 18.<\/p>\n PMID: 30885980<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.<\/a><\/p>\n O’Reilly E, Tuzova AV, Walsh AL, Russell NM, O’Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O’Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM<\/strong>, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J,\u00a0Perry AS<\/strong>.<\/p>\n JCO Precis Oncol. 2019;2019. doi: 10.1200\/PO.18.00134. Epub 2019 Jan 14.<\/p>\n PMID: 30801051 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes.<\/a><\/p>\n Glezeva N, Moran B, Collier P, Moravec CS, Phelan D, Donnellan E, Russell-Hallinan A, O’Connor DP,\u00a0Gallagher WM<\/strong>, Gallagher J, McDonald K, Ledwidge M, Baugh J, Das S, Watson CJ.<\/p>\n Circ Heart Fail. 2019 Mar;12(3):e005765. doi: 10.1161\/CIRCHEARTFAILURE.118.005765.<\/p>\n PMID: 30798618<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate.<\/a><\/p>\n O’Farrell AC, Miller IS, Evans R, Alamanou M, Cary M, Mallya Udupi G, Lafferty A, Monsefi N, Cremona M, Prehn JHM, Verheul HM,\u00a0Gallagher WM<\/strong>, Gehrmann M, Byrne AT.<\/p>\n Proteomics Clin Appl. 2019 Jul;13(4):e1800159. doi: 10.1002\/prca.201800159. Epub 2019 Mar 19.<\/p>\n PMID: 30768761<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n PEGylated BF2<\/sub>-Azadipyrromethene (NIR-AZA) fluorophores, for intraoperative imaging.<\/a><\/p>\n Wu D, Daly HC, Conroy E, Li B,\u00a0Gallagher WM<\/strong>, Cahill RA, O’Shea DF.<\/p>\n Eur J Med Chem. 2019 Jan 1;161:343-353. doi: 10.1016\/j.ejmech.2018.10.046. Epub 2018 Oct 19.<\/p>\n PMID: 30368132<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.<\/a><\/p>\n Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R, Hanna MY, Mills R, Tuzova AV, O’Reilly E, Kelly S, Cooper C; Movember Urine Biomarker Consortium, Brewer D,\u00a0Perry AS<\/strong>, Clark J, Fleshner N, Bapat B.<\/p>\n Clin Epigenetics. 2018 Nov 23;10(1):147. doi: 10.1186\/s13148-018-0575-z.<\/p>\n PMID: 30470249 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.<\/a><\/p>\n Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O’Leary P, Holmes FA, Espina V, Liotta LA, O’Shaughnessy J, Gallagher C, O’Driscoll L, Rani S, Madden SF, O’Brien NA, Ginther C, Slamon D, Walsh N,\u00a0Gallagher WM<\/strong>, Zagozdzon R, Watson WR, O’Donovan N, Crown J.<\/p>\n BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186\/s12885-018-4852-1.<\/p>\n PMID: 30305055\u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.<\/a><\/p>\n Smeets D, Miller IS, O’Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N,\u00a0Gallagher WM<\/strong>, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.<\/p>\n Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038\/s41467-018-06567-6.<\/p>\n PMID: 30291241 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers.<\/a><\/p>\n Lindner AU, Lucantoni F, Vare\u0161lija D, Resler A, Murphy BM,\u00a0Gallagher WM<\/strong>, Hill ADK, Young LS, Prehn JHM.<\/p>\n J Mol Med (Berl). 2018 Oct;96(10):1025-1037. doi: 10.1007\/s00109-018-1675-0. Epub 2018 Aug 1.<\/p>\n PMID: 30069746<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer.<\/a><\/p>\n Murphy K, Murphy BT, Boyce S, Flynn L, Gilgunn S, O’Rourke CJ, Rooney C, St\u00f6ckmann H, Walsh AL, Finn S, O’Kennedy RJ, O’Leary J, Pennington SR,\u00a0Perry AS<\/strong>, Rudd PM, Saldova R, Sheils O, Shields DC, Watson RW.<\/p>\n Mol Oncol. 2018 Sep;12(9):1513-1525. doi: 10.1002\/1878-0261.12348. Epub 2018 Aug 7.<\/p>\n PMID: 29927052 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Epigenetics of malignant melanoma.<\/a><\/p>\n Moran B, Silva R, Perry AS,<\/strong>Gallagher WM<\/strong>.<\/p>\n Semin Cancer Biol. 2018 Aug;51:80-88. doi: 10.1016\/j.semcancer.2017.10.006. Epub 2017 Oct 23. Review.<\/p>\n PMID: 29074395<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.<\/a><\/p>\n van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW,\u00a0Gallagher WM<\/strong>, O’Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.<\/p>\n J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200\/JCO.2017.77.1782. Epub 2018 May 24.<\/p>\n PMID: 29792754<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Role of serum response factor expression in prostate cancer biochemical recurrence.<\/a><\/p>\n Prencipe M<\/strong>, Fabre A, Murphy TB, Vargyas E, O’Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W<\/strong>, Watson RW.<\/p>\n Prostate. 2018 Jul;78(10):724-730. doi: 10.1002\/pros.23516. Epub 2018 Apr 2.<\/p>\n PMID: 29608018<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Innovative Technologies Changing Cancer Treatment.<\/a><\/p>\n Charmsaz S,\u00a0Prencipe M<\/strong>, Kiely M, Pidgeon GP, Collins DM.<\/p>\n Cancers (Basel). 2018 Jun 19;10(6). pii: E208. doi: 10.3390\/cancers10060208.<\/p>\n PMID: 29921753\u00a0 \u00a0Free PMC Article<\/a><\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.<\/a><\/p>\n O’Brien KP, Khan S, Gilligan KE, Zafar H, Lalor P, Glynn C, O’Flatharta C, Ingoldsby H, Dockery P, De Bhulbh A, Schweber JR, St John K, Leahy M, Murphy JM,\u00a0Gallagher WM<\/strong>, O’Brien T, Kerin MJ, Dwyer RM.<\/p>\n Oncogene. 2018 Apr;37(16):2137-2149. doi: 10.1038\/s41388-017-0116-9. Epub 2018 Jan 25.<\/p>\n PMID: 29367765<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Assessing DNA Methylation in Cancer Stem Cells.<\/a><\/p>\n Das S, Moran B,\u00a0Perry AS<\/strong>.<\/p>\n Methods Mol Biol. 2018;1692:157-178. doi: 10.1007\/978-1-4939-7401-6_15.<\/p>\n PMID: 28986896<\/p>\n ________________________________________________________________________________________________________________________<\/p>\n Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.<\/a><\/p>\n Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O’Donovan N, O’Connor D,\u00a0Gallagher WM<\/strong>, Crown J, Fersht AR, Duffy MJ.<\/p>\n Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016\/j.canlet.2017.09.053. Epub 2017 Oct 22.<\/p>\n PMID: 29069577<\/p>\n ________________________________________________________________________________________________________________________ O’Brien KP, Khan S, Gilligan KE, Zafar H, Lalor P, Glynn C, O’Flatharta C, Ingoldsby H, Dockery P, De Bhulbh A, Schweber JR, St John K, Leahy M, Murphy JM,
<\/p>\n\n\n\n
Res Involv Engagem. 2023 Oct 12;9(1):90. doi: 10.1186\/s40900-023-00500-y. PMID: 37821914 PMCID: PMC10568930<\/p>\n\n\n\n
Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.<\/a><\/p>\n